Adoption of Lutetium-¹⁷⁷ PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020.

ABSTRACT:

Purpose

This study is to investigate the adoption and current trends of Lutetium-¹⁷⁷ PSMA RLT for mCRPC in Germany.

Methods

We analyzed data from the reimbursement.INFO tool based on German hospitals' quality reports for Lutetium-¹⁷⁷ PSMA RLT from 2016 to 2020 and from the nationwide German hospital billing database (Destatis) for general therapy with open radionuclides in combination with prostate cancer from 2006 to 2020. For validation of these billing data, we included the ¹⁷⁷Lu-PSMA RLT cycles from two participating institutions from 2016 to 2020. For detection of trends over time we applied linear regression models.

Results

General therapy with open radionuclides increased from 2006 to 2020. We identified a total of 12,553 ¹

SUBMITTER: Flegar L 

PROVIDER: S-EPMC10199877 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature